疫苗前沿 | 預防老年人嚴重呼吸道疾病效力為80%,楊森RSV疫苗達到2b期臨床終點

疫苗前沿 | 預防老年人嚴重呼吸道疾病效力為80%,楊森RSV疫苗達到2b期臨床終點

戳藍色字“預防界”關注我們喲

疫苗前沿 | 預防老年人嚴重呼吸道疾病效力為80%,楊森RSV疫苗達到2b期臨床終點

參考資料:

[1] Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults。 Retrieved October 3, 2021, from https://www。janssen。com/janssen-announces-start-phase-3-trial-investigational-respiratory-syncytial-virus-rsv-vaccine-older

[2] Janssen Announces Phase 2b Data Demonstrating its Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Infections in Older Adults。 Retrieved October 3, 2021, from https://www。prnewswire。com/news-releases/janssen-announces-phase-2b-data-demonstrating-its-investigational-rsv-adult-vaccine-provided-80-protection-against-lower-respiratory-infections-in-older-adults-301391246。html

END

本公眾號所有轉載文章系出於傳遞更多資訊之目的,且明確註明來源和作者,不希望被轉載的媒體或個人可與我們聯絡,我們將立即進行刪除處理。所有文章僅代表作者觀點,不代表本站立場。

歡迎留言、討論、轉發,同時,我們也向業內人士長期徵稿,點選主選單下方“聯絡我們”,獲取方式!

TAG: janssenAnnouncesPhaseInvestigational